Screening Approaches for Reducing Attrition Due to Drug-induced Liver Injury (DILI) Early in Drug Discovery
Date: Wednesday, June 10, 2020
Time: 9:00am PDT / 12:00pm EDT
Duration: 1 hour
Drug-induced liver injury (DILI) is a leading cause of drug failures in clinical trials and the major reason for drug withdrawals from the market. It is very challenging to predict DILI because the causes of DILI are multifactorial. Recent advances in in vitro liver toxicity testing have enabled significant improvements in detecting potential compound-mediated liver toxicities early in drug discovery.
In this webinar, we will discuss a set of in vitro assays that tackle the challenges of in vitro hepatotoxicity assessment. We will discuss the utilization of a portfolio of cell-based in vitro assays, including assays that assess mitochondrial dysfunction, toxic effect by reactive metabolites, induction of reactive oxygen species (ROS), and cholestasis. We will also discuss the major cell types that are used in in vitro hepatotoxicity screening.
Attendees will learn about the Eurofins Discovery approach for assessing DILI using high-throughput screening and mechanistic panels to improve the detection of potential hepatotoxicity.
Yong Zhao, Ph.D.
Director of In Vitro Toxicology Services